… Patients received two cycles of induction chemotherapy with carboplatin and paclitaxel
followed by radiation administered concurrently with weekly doses of carboplatin and …

… study in which 878 patients with recurrent or advanced non–small-cell lung cancer (stage
IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or …

… favoring the chemotherapy group (HR=0.69; 95% CI: 0.48–0.98; p=0.035). With regard to
lung cancer mortality, there have been 19 lung cancer deaths in the chemotherapy group and …

… atezolizumab plus chemotherapy (carboplatin plus nab-paclitaxel) versus chemotherapy
alone … -squamous non-small-cell lung cancer who have not previously received chemotherapy. …

… -small cell lung cancer (NSCLC). Paclitaxel-based combination chemotherapy, particularly
… conclusions of several studies regarding paclitaxel-based chemotherapy. The data provide …

… reported and ongoing Phase I studies with paclitaxel in combination with other drugs … -small
cell lung cancer. Preliminary results of a Phase I study of paclitaxel and cyclophosphamide …

… metastatic non–small-cell lung cancer is only four to five … Chemotherapy for advanced
non–small-cell lung cancer is often … carboplatin/paclitaxel for advanced nonsmall cell lung cancer…

… and paclitaxel doublet chemotherapy … paclitaxel doublet chemotherapy compared with
gemcitabine or vinorelbine monotherapy showed a survival benefit with the doublet chemotherapy…

Objective: Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell
lung cancer (NSCLC). The aim of this study was to evaluate the activity and toxicity of …

… and toxicity of paclitaxel and gemcitabine (PG) and paclitaxel and … -cell lung cancer (NSCLC).
PATIENTS AND METHODS: Chemotherapy-naive patients were randomized to paclitaxel …